Compare Stocks

→ Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNA Allena Pharmaceuticals		$0.07	$0.06 ▼ $1.17	$37K	1.13	15.69 million shs	96,558 shs
BVXV BiondVax Pharmaceuticals		$1.36	$1.25 ▼ $11.80	$2.54M	2.37	127,289 shs	23,000 shs
NTGN Neon Therapeutics	$3.07	$3.03	$0.88 ▼ $6.25	$88.93M	-0.81	516,108 shs	N/A
OTLK Outlook Therapeutics	$8.19 -0.1%	$8.59	$4.00 ▼ $40.60	$106.58M	0.04	530,385 shs	150,455 shs

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNA Allena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
BVXV BiondVax Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-26.49%
NTGN Neon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OTLK Outlook Therapeutics	0.00%	-4.76%	-3.64%	-5.73%	-62.39%

A new way to collect income from stocks (Ad)

Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…

Click here to see me place one of these trades LIVE on camera.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	2.8315 of 5 stars	3.4	4.0	0.0	0.0	2.8	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	466.85% Upside

Current Analyst Ratings

Latest ALNA, BVXV, NTGN, and OTLK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00
1/25/2024	OTLK Outlook Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40
1/25/2024	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$40.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	$0.23 per share	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	($3.81) per share	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	$0.50 per share	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNA Allena Pharmaceuticals	-$48.66M	N/A	0.00	N/A	N/A	N/A	-287.46%	-146.58%	N/A
BVXV BiondVax Pharmaceuticals	-$5.80M	-$2.55	N/A	N/A	N/A	N/A	-346.36%	-29.52%	N/A
NTGN Neon Therapeutics	-$79.78M	-$2.86	N/A	N/A	N/A	N/A	-199.09%	-137.14%	N/A
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)

Latest ALNA, BVXV, NTGN, and OTLK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BVXV BiondVax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NTGN Neon Therapeutics	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNA Allena Pharmaceuticals	N/A	1.58	1.58
BVXV BiondVax Pharmaceuticals	N/A	4.12	4.12
NTGN Neon Therapeutics	0.43	1.58	3.00
OTLK Outlook Therapeutics	N/A	0.44	0.44

Ownership

Institutional Ownership

Company	Institutional Ownership
ALNA Allena Pharmaceuticals	7.33%
BVXV BiondVax Pharmaceuticals	11.83%
NTGN Neon Therapeutics	54.71%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
ALNA Allena Pharmaceuticals	3.70%
BVXV BiondVax Pharmaceuticals	6.03%
NTGN Neon Therapeutics	38.93%
OTLK Outlook Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNA Allena Pharmaceuticals	35	122.08 million	117.57 million	Not Optionable
BVXV BiondVax Pharmaceuticals	33	1.87 million	1.76 million	Not Optionable
NTGN Neon Therapeutics	102	28.97 million	N/A	Not Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable

ALNA, BVXV, NTGN, and OTLK Headlines

Source	Headline
	Best's Market Segment Report: AM Best Revises Outlook on London Market Insurance Segment to Positive finance.yahoo.com - April 22 at 1:21 PM
	USD/JPY Forecast: BoJ’s Rate Hike Talks and the Yen’s Outlook fxempire.com - April 22 at 1:21 PM
	WGA Releases New Housing Finance Outlook markets.businessinsider.com - April 22 at 1:21 PM
	Outlook Money’s Tushar Ghosh elevated to Publishing Director pitchonnet.com - April 22 at 1:21 PM
	Outlook: How to set up breaks between your meetings msn.com - April 22 at 1:21 PM
	Outlook Therapeutics, Inc. (OTLK) finance.yahoo.com - April 21 at 8:02 PM
	World Economic Outlook: IMF revises GDP predictions for LATAM and the Carribbean invezz.com - April 18 at 6:25 PM
	World Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Prices finance.yahoo.com - April 18 at 6:25 PM
	Economic Outlook 2024 in Springfield connectionnewspapers.com - April 18 at 6:25 PM
	Bosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024 usnews.com - April 18 at 6:25 PM
	Reporter's Guarentee \| Outlook's Rakhi Bose In Conversation With Dalit Villagers In Saharanpur District outlookindia.com - April 18 at 6:25 PM
	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million globenewswire.com - April 15 at 4:15 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	Outlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrast americanbankingnews.com - April 15 at 1:14 AM
	US Consumer Sentiment Falls Slightly as Outlook for Inflation Worsens msn.com - April 14 at 9:03 AM
	Microsoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot? msn.com - April 14 at 9:03 AM
	Fed's Williams: Outlook is uncertain, Fed must be data-dependent fxstreet.com - April 11 at 6:05 PM
	National Gas’ Summer Outlook 2024: Stable supply, reduced exports energylivenews.com - April 11 at 6:05 PM
	ADB Outlook forecasts 7 % GDP growth in 2025 bbs.bt - April 11 at 6:05 PM
	Natural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlook fxempire.com - April 11 at 1:44 AM
	Stock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cut msn.com - April 11 at 1:44 AM
	Bitdefender now has identity protection for Gmail and Outlook msn.com - April 11 at 1:44 AM
	Insiders are Piling into These 10 Healthcare Stocks in 2024 finance.yahoo.com - April 10 at 3:44 PM
	Users Complain Gmail Blocks Email From Microsoft Outlook—Here’s The Fix forbes.com - April 3 at 3:14 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allena Pharmaceuticals

NASDAQ:ALNA

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

BiondVax Pharmaceuticals

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Neon Therapeutics

NASDAQ:NTGN

Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial